ROLFE PANCREATIC CANCER FOUNDATION

SHOP CONTACT
DONATE

BREAKTHROUGH IN PANCREATIC CANCER STUDY

Cancer Interception Study Offers New Hope

Stopping Pancreatic Cancer Before It Starts

A groundbreaking study published in Science is offering new hope in the fight against pancreatic cancer. Researchers from the University of Pennsylvania and Johns Hopkins University explored a promising approach called “cancer interception,” which focuses on stopping cancer before it fully develops.

In the study, scientists used KRAS inhibitor drugs to target precancerous pancreatic lesions known as PanINs. These lesions commonly carry KRAS mutations that drive the development of pancreatic cancer. When treated with these inhibitors in preclinical models, the lesions shrank or disappeared, delaying tumor development and significantly improving survival. In long-term studies, mice receiving treatment lived nearly three times longer than those that did not.

Because pancreatic cancer is often diagnosed at a late stage, strategies that stop the disease earlier could dramatically change outcomes for individuals at high risk.

How Rolfe Foundation Supports Breakthrough Research

Rolfe Pancreatic Cancer Foundation is proud to have helped support this research through funding for Dr. Ashley Kiemen at Johns Hopkins University, whose work contributed to this landmark publication.

For 26 years, The Foundation has been committed to advancing innovative research that moves the field forward. Discoveries like this show the real impact of that support—and bring us closer to a future where pancreatic cancer can be stopped before it starts.

dr. ashley kieman from breakthrough study

Join the Fight: Support the Next Breakthrough

Breakthroughs like this are made possible by a community that believes progress is possible. With your support, we can continue funding the scientists and discoveries working to change the future of pancreatic cancer.

Support the next breakthrough. Donate today.